AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3229297 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg L-acetylcarnitine
Number of subjects: 10
Study 3229297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31041883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention conditions in group randomized trials, specific details not provided.
Number of subjects: 0
Study 31041883 — intervention group
Group type: COMPARATOR
Intervention: Control conditions in group randomized trials, specific details not provided.
Number of subjects: 0
Study 31041883 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-objective optimal designs, specific details not provided.
Number of subjects: 0
Study 28944646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - twelve 1-minute bouts at 95% estimated maximum workload (eWLmax) interspersed with 1-minute bouts at 40% eWLmax
Number of subjects: 22
Study 28944646 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) - 26 minutes at 55% estimated maximum workload (eWLmax)
Number of subjects: 22
Study 26023808 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal-plane plyometric (FPP) training
Number of subjects: 14
Study 26023808 — intervention group
Group type: COMPARATOR
Intervention: Sagittal-plane plyometric (SPP) training
Number of subjects: 14
Study 26674200 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 11
Study 26674200 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 11
Study 26674200 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 11
Study 23910199 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self-ligation brackets
Number of subjects: 96
Study 23910199 — intervention group
Group type: EXPERIMENTAL
Intervention: Active self-ligation brackets
Number of subjects: 96
Study 23910199 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon Q brackets
Number of subjects: 96
Study 23910199 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 96
Study 21982758 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L/min O(2) via a demand system during sleep (n = 3)
Number of subjects: 15
Study 21982758 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L/min O(2)/CO(2) mix (1.5% CO(2)) via a demand system during sleep (n = 4)
Number of subjects: 15
Study 21982758 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg acetazolamide 30 minutes before bedtime (n = 4)
Number of subjects: 15
Study 21982758 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 4)
Number of subjects: 15
Study 18781275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg over 24 h
Number of subjects: 50
Study 18781275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16861397 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM pain management program
Number of subjects: 37
Study 16861397 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 37
Study 12854104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Number of subjects: 0
Study 12854104 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (standard peripheral intravenous nutrition with topical GTN only)
Number of subjects: 0
Study 12854104 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Number of subjects: 0
Study 10873990 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (10 Gy in five fractions over 5-7 days)
Number of subjects: 39
Study 10873990 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 39
Study 8677204 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 12
Study 8677204 — intervention group
Group type: COMPARATOR
Intervention: Control group (obese, mildly hypertensive males)
Number of subjects: 12
Study 8677204 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA patients
Number of subjects: 12
Study 2398189 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 08 Canal Finder System
Number of subjects: 270
Study 2398189 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 10 K‐file
Number of subjects: 270
Study 2398189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathfinder
Number of subjects: 270
Study 6103299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diethylcarbamazine citrate (DEC)
Number of subjects: 20
Study 6103299 — intervention group
Group type: COMPARATOR
Intervention: Topical diethylcarbamazine (DEC) lotion
Number of subjects: 20
Study 6103299 — intervention group
Group type: COMPARATOR
Intervention: Both groups (oral and topical DEC)
Number of subjects: 20
Study 31820059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin (30 International Units Insulin Regular in 30 ml of normal saline)
Number of subjects: 110
Study 31820059 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing with normal saline (control group)
Number of subjects: 110
Study 30237571 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fish consumption 3 or more times per week during the last trimester of pregnancy
Number of subjects: 56
Study 30237571 — intervention group
Group type: COMPARATOR
Intervention: Maternal fish consumption 0-2 times per week during the last trimester of pregnancy
Number of subjects: 56
Study 28146651 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal-flow LVAD (study device)
Number of subjects: 446
Study 28146651 — intervention group
Group type: COMPARATOR
Intervention: Axial-flow LVAD (control device)
Number of subjects: 446
Study 25459392 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM) at a dosage of 1.000mg/m² d1, 8, 15 q28
Number of subjects: 106
Study 25459392 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sunitinib (SUNGEM) with GEM 1.000mg/m² d1+8 and sunitinib 50mg p.o. d1-14, q21d
Number of subjects: 106
Study 25459392 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM)
Number of subjects: 106
Study 25459392 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sunitinib (SUNGEM)
Number of subjects: 106
Study 23780899 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetsuit worn out of water
Number of subjects: 8
Study 23780899 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetsuit during immersion
Number of subjects: 8
Study 23780899 — intervention group
Group type: COMPARATOR
Intervention: No wetsuit worn out of water (control)
Number of subjects: 8
Study 23780899 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetsuit scuba-immersed sessions at 1, 6 and 12 msw depth
Number of subjects: 8
Study 21959870 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-β (EPO) 36,000 IU weekly for 12 weeks
Number of subjects: 186
Study 21959870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 21959870 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-β (EPO) and Placebo
Number of subjects: 186
Study 19567317 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 20
Study 19567317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (100 mJ, 20 Hz)
Number of subjects: 20
Study 16489080 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d
Number of subjects: 171
Study 16489080 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 171
Study 15369422 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician Letter arm
Number of subjects: 2614
Study 15369422 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician/Member Letter arm
Number of subjects: 2614
Study 15369422 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2614
Study 15369422 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial modeling analysis
Number of subjects: 2614
Study 11102251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase 120 KU/kg as a single intravenous bolus
Number of subjects: 15078
Study 11102251 — intervention group
Group type: COMPARATOR
Intervention: Accelerated alteplase up to 100 mg given over 90 min
Number of subjects: 15078
Study 9470884 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch (24 hour transdermal nicotine patch over a 10 week course)
Number of subjects: 305
Study 9470884 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine patch
Number of subjects: 305
Study 7958544 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomeric insulin analogue [Lys(B28),Pro(B29)] (MI)
Number of subjects: 0
Study 7958544 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 0
Study 2884796 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg X kg‐1
Number of subjects: 34
Study 2884796 — intervention group
Group type: EXPERIMENTAL
Intervention: pipecuronium 0.1 mg X kg‐1
Number of subjects: 34
Study 2884796 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg X kg‐1
Number of subjects: 34
Study 29458408 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Number of subjects: 120
Study 29458408 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopic Surgical Ablation
Number of subjects: 120
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-containing supplements ≥3 days/week
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) (min/d)
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor walking during school hours (min/week)
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per year)
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling in October
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling in November
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-white ethnicity
Number of subjects: 782
Study 26563915 — intervention group
Group type: EXPERIMENTAL
Intervention: Immigrant/descendant background
Number of subjects: 782
Study 24670200 — intervention group
Group type: EXPERIMENTAL
Intervention: QualiCCare education for GPs
Number of subjects: 288
Study 24670200 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 288
Study 22388300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive stents (BAS)
Number of subjects: 425
Study 22388300 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 425
Study 20811077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program (proprioception + GMS)
Number of subjects: 48
Study 20811077 — intervention group
Group type: EXPERIMENTAL
Intervention: GMS training
Number of subjects: 48
Study 20811077 — intervention group
Group type: COMPARATOR
Intervention: Proprioception training
Number of subjects: 48
Study 18193397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium yeast (300 microg/day)
Number of subjects: 42
Study 15993459 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused spatial attention
Number of subjects: 0
Study 15993459 — intervention group
Group type: COMPARATOR
Intervention: Pooling mechanism
Number of subjects: 0
Study 12627405 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed treatment method based on joint toxicity and efficacy
Number of subjects: 0
Study 12627405 — intervention group
Group type: COMPARATOR
Intervention: Usual tests
Number of subjects: 0
Study 9831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride dentifrice (F = 1,250 ppm)
Number of subjects: 12
Study 9831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/sodium fluoride mouthrinse (total F = 250 ppm)
Number of subjects: 12
Study 9831781 — intervention group
Group type: COMPARATOR
Intervention: Amine fluoride dentifrice alone
Number of subjects: 12
Study 9831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride dentifrice combined with fluoride mouthrinse
Number of subjects: 12
Study 8644905 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 170
Study 8644905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 1530022 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrostep
Number of subjects: 100
Study 1530022 — intervention group
Group type: EXPERIMENTAL
Intervention: Loestrin
Number of subjects: 100
Study 1530022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3921141 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 25
Study 3921141 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 25
Study 30220726 — intervention group
Group type: EXPERIMENTAL
Intervention: WEBB program (n=13)
Number of subjects: 35
Study 30220726 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral balance training (n=12)
Number of subjects: 35
Study 30220726 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 35
Study 26643085 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 4 weeks for 12 weeks
Number of subjects: 73
Study 26643085 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate every 4 weeks for 12 weeks
Number of subjects: 73
Study 25246489 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/day
Number of subjects: 42
Study 25246489 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 60 mg/day
Number of subjects: 42
Study 25246489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22540412 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implants (mismatch 0.35-0.40 mm)
Number of subjects: 80
Study 22540412 — intervention group
Group type: COMPARATOR
Intervention: Conventional implants (control)
Number of subjects: 80
Study 22540412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 80
Study 20730060 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg bid (n = 60)
Number of subjects: 115
Study 20730060 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg qd (n = 55)
Number of subjects: 115
Study 20730060 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (both dosing regimens)
Number of subjects: 115
Study 18680178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 20
Study 16183682 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% alone
Number of subjects: 60
Study 16183682 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 3 microg ml(‐1)
Number of subjects: 60
Study 16183682 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with clonidine 0.6 microg ml(‐1)
Number of subjects: 60
Study 16183682 — intervention group
Group type: COMPARATOR
Intervention: All groups (bupivacaine alone, bupivacaine with fentanyl, bupivacaine with clonidine)
Number of subjects: 60
Study 12861131 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (5 mg/d for 13 days every 3 months)
Number of subjects: 25
Study 12861131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10391093 — intervention group
Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in normal squamous epithelium
Number of subjects: 0
Study 10391093 — intervention group
Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in Barrett's epithelium
Number of subjects: 0
Study 10391093 — intervention group
Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in adenocarcinoma
Number of subjects: 0
Study 10391093 — intervention group
Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in squamous cell carcinoma
Number of subjects: 0
Study 8873228 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1000 mg once daily)
Number of subjects: 198
Study 8873228 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg once daily)
Number of subjects: 198
Study 1387806 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus amikacin
Number of subjects: 158
Study 1387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin plus teicoplanin
Number of subjects: 158
Study 1387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin with teicoplanin after 72 hours
Number of subjects: 158
Study 1387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin plus amphotericin B after 72 hours
Number of subjects: 158
Study 1387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 158
Study 1387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial empirical regimen with antibiotics active against gram-positive organisms
Number of subjects: 158
Study 7091512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy
Number of subjects: 67
Study 7091512 — intervention group
Group type: COMPARATOR
Intervention: Nonsympathectomy
Number of subjects: 67
Study 7091512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 30113522 — intervention group
Group type: EXPERIMENTAL
Intervention: whey protein (25 g) plus HMB (1.5 g)
Number of subjects: 26
Study 30113522 — intervention group
Group type: COMPARATOR
Intervention: whey protein (25 g) plus leucine (1.5 g)
Number of subjects: 26
Study 30562371 — intervention group
Group type: EXPERIMENTAL
Intervention: African Descent (AD)
Number of subjects: 260
Study 30562371 — intervention group
Group type: EXPERIMENTAL
Intervention: European Descent (ED)
Number of subjects: 260
Study 30562371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Descent (MD)
Number of subjects: 260
Study 30562371 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison among groups
Number of subjects: 260
Study 27223310 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Navigation
Number of subjects: 56
Study 27223310 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 24584876 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doxorubicin-cyclophosphamide followed by paclitaxel with bevacizumab therapy (duration not specified)
Number of subjects: 124
Study 24584876 — intervention group
Group type: COMPARATOR
Intervention: Standard doxorubicin-cyclophosphamide followed by paclitaxel with placebo
Number of subjects: 124
Study 22965699 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine combined with Chinese medicine (CM) treatment
Number of subjects: 125
Study 22965699 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Amlodipine Besylate Tablets and Irbesartan Tablets or Irbesartan and Hydrochlorothiazide Tablets)
Number of subjects: 125
Study 19575284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 294
Study 19575284 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 294
Study 18845709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PS dose consumed as an afternoon snack (1.6 g/d)
Number of subjects: 26
Study 18845709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PS dose consumed with a meal (1.6 g/d)
Number of subjects: 26
Study 18845709 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 26
Study 18845709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PS dose consumed as an afternoon snack
Number of subjects: 26
Study 18845709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PS dose consumed with a meal
Number of subjects: 26
Study 16150741 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (diagnostic and treatment algorithm, small group sessions, videotapes, written material, outreach visits, one-on-one interviews with physicians)
Number of subjects: 4217
Study 16150741 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4217
Study 16150741 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 4217
Study 12393997 — intervention group
Group type: EXPERIMENTAL
Intervention: CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil)
Number of subjects: 145
Study 12393997 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 145
Study 10202165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m² per week for six weeks (group 1)
Number of subjects: 526
Study 10202165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m² on days 1 and 29, 4 g of fluorouracil per m² as a 96-hour infusion on days 1 and 29, and 2 g of oral hydroxyurea twice weekly for six weeks (group 2)
Number of subjects: 526
Study 10202165 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea 3 g/m² twice weekly for six weeks (group 3)
Number of subjects: 526
Study 7869476 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (alpha 1‐adrenergic receptor antagonist)
Number of subjects: 18
Study 7869476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2611090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1.95 g day‐1 for 1 week
Number of subjects: 8
Study 2611090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 3.25 g day‐1 for 1 week
Number of subjects: 8
Study 2611090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 4.55 g day‐1 for 1 week
Number of subjects: 8
Study 2611090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 5.85 g day‐1 for 1 week
Number of subjects: 8
Study 30703643 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot landing (FFOOT)
Number of subjects: 18
Study 30703643 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward trunk lean (FTL)
Number of subjects: 18
Study 30703643 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% step rate increase (SR10%)
Number of subjects: 18